BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 7692816)

  • 1. Synergistic drug interactions of an HIV-1 protease inhibitor with AZT in different in vitro models of HIV-1 infection.
    Lambert DM; Bartus H; Fernandez AV; Bratby-Anders C; Leary JJ; Dreyer GB; Metcalf BW; Petteway SR
    Antiviral Res; 1993 Aug; 21(4):327-42. PubMed ID: 7692816
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CGP 53437, an orally bioavailable inhibitor of human immunodeficiency virus type 1 protease with potent antiviral activity.
    Alteri E; Bold G; Cozens R; Faessler A; Klimkait T; Lang M; Lazdins J; Poncioni B; Roesel JL; Schneider P
    Antimicrob Agents Chemother; 1993 Oct; 37(10):2087-92. PubMed ID: 8257128
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of human immunodeficiency virus type 1 replication by combination of transcription inhibitor K-12 and other antiretroviral agents in acutely and chronically infected cells.
    Okamoto M; Okamoto T; Baba M
    Antimicrob Agents Chemother; 1999 Mar; 43(3):492-7. PubMed ID: 10049256
    [TBL] [Abstract][Full Text] [Related]  

  • 4. AZT (zidovudine) may act postintegrationally to inhibit generation of HIV-1 progeny virus in chronically infected cells.
    Rooke R; Tremblay M; Wainberg MA
    Virology; 1990 May; 176(1):205-15. PubMed ID: 1691885
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Relative potency of protease inhibitors in monocytes/macrophages acutely and chronically infected with human immunodeficiency virus.
    Perno CF; Newcomb FM; Davis DA; Aquaro S; Humphrey RW; CaliĆ² R; Yarchoan R
    J Infect Dis; 1998 Aug; 178(2):413-22. PubMed ID: 9697721
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interferon-alpha but not AZT suppresses HIV expression in chronically infected cell lines.
    Poli G; Orenstein JM; Kinter A; Folks TM; Fauci AS
    Science; 1989 May; 244(4904):575-7. PubMed ID: 2470148
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bisheteroarylpiperazine reverse transcriptase inhibitor in combination with 3'-azido-3'-deoxythymidine or 2',3'-dideoxycytidine synergistically inhibits human immunodeficiency virus type 1 replication in vitro.
    Chong KT; Pagano PJ; Hinshaw RR
    Antimicrob Agents Chemother; 1994 Feb; 38(2):288-93. PubMed ID: 7514857
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characteristics of a group of nonnucleoside reverse transcriptase inhibitors with structural diversity and potent anti-human immunodeficiency virus activity.
    Yang SS; Fliakas-Boltz V; Bader JP; Buckheit RW
    Leukemia; 1995 Oct; 9 Suppl 1():S75-85. PubMed ID: 7475321
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synergistic antiviral effect of PEG-asparaginase (ONCASPAR), with protease inhibitor alone and in combination with RT inhibitors against HIV-1 infected T-cells: a model of HIV-1-induced T-cell lymphoma.
    Avramis VI; Kwock R; Avramis IA; Cohen LJ; Inderlied C
    In Vivo; 2001; 15(1):1-9. PubMed ID: 11286117
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of the protease of human immunodeficiency virus blocks replication and infectivity of the virus in chronically infected macrophages.
    Perno CF; Bergamini A; Pesce CD; Milanese G; Capozzi M; Aquaro S; Thaisrivongs S; Tarpley WG; Zon G; D'Agostini C
    J Infect Dis; 1993 Nov; 168(5):1148-56. PubMed ID: 8228348
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Incorporation of 12-methoxydodecanoate into the human immunodeficiency virus 1 gag polyprotein precursor inhibits its proteolytic processing and virus production in a chronically infected human lymphoid cell line.
    Bryant ML; Ratner L; Duronio RJ; Kishore NS; Devadas B; Adams SP; Gordon JI
    Proc Natl Acad Sci U S A; 1991 Mar; 88(6):2055-9. PubMed ID: 2006142
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro anti-HIV-1 activity of HIV protease inhibitor KNI-272 in resting and activated cells: implications for its combined use with AZT or ddI.
    Chokekijchai S; Shirasaka T; Weinstein JN; Mitsuya H
    Antiviral Res; 1995 Sep; 28(1):25-38. PubMed ID: 8585758
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HIV-1 proteinase is required for synthesis of pro-viral DNA.
    Baboonian C; Dalgleish A; Bountiff L; Gross J; Oroszlan S; Rickett G; Smith-Burchnell C; Troke P; Merson J
    Biochem Biophys Res Commun; 1991 Aug; 179(1):17-24. PubMed ID: 1652947
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antiviral activity of human immunodeficiency virus type 1 protease inhibitors in a single cycle of infection: evidence for a role of protease in the early phase.
    Nagy K; Young M; Baboonian C; Merson J; Whittle P; Oroszlan S
    J Virol; 1994 Feb; 68(2):757-65. PubMed ID: 8289379
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synergistic combinations and peptides in the inhibition of human immunodeficiency virus.
    Cox S; Koshida R; Harmenberg J; Wahren B
    Adv Enzyme Regul; 1991; 31():85-97. PubMed ID: 1715118
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vitro selection of human immunodeficiency virus type 1 resistant to 3'-azido-3'-deoxythymidine.
    Dianzani F; Antonelli G; Turriziani O; Dong G; Capobianchi MR; Riva E
    Antiviral Res; 1992 May; 18(1):39-52. PubMed ID: 1384427
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Drug resistance and drug combination features of the human immunodeficiency virus inhibitor, BCH-10652 [(+/-)-2'-deoxy-3'-oxa-4'-thiocytidine, dOTC].
    Taylor DL; Ahmed PS; Tyms AS; Wood LJ; Kelly LA; Chambers P; Clarke J; Bedard J; Bowlin TL; Rando RF
    Antivir Chem Chemother; 2000 Jul; 11(4):291-301. PubMed ID: 10950391
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Selective and synergistic inhibition of human immunodeficiency virus type 1 reverse transcriptase by a non-nucleoside inhibitor, MKC-442.
    Yuasa S; Sadakata Y; Takashima H; Sekiya K; Inouye N; Ubasawa M; Baba M
    Mol Pharmacol; 1993 Oct; 44(4):895-900. PubMed ID: 7694070
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anti-human immunodeficiency virus (HIV) activities of halogenated gomisin J derivatives, new nonnucleoside inhibitors of HIV type 1 reverse transcriptase.
    Fujihashi T; Hara H; Sakata T; Mori K; Higuchi H; Tanaka A; Kaji H; Kaji A
    Antimicrob Agents Chemother; 1995 Sep; 39(9):2000-7. PubMed ID: 8540706
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vitro activity of inhibitors of late stages of the replication of HIV in chronically infected macrophages.
    Perno CF; Aquaro S; Rosenwirth B; Balestra E; Peichl P; Billich A; Villani N; CaliĆ² R
    J Leukoc Biol; 1994 Sep; 56(3):381-6. PubMed ID: 8083612
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.